文献速递血栓与止血

凝血因子IXa结合区Lys1813Ala突变的凝血因子VIII增强内源性凝血潜能

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential.
PubMed 文献 · Blood Adv · 2023-01-01

研究旨在鉴定1811-1818区可增强凝血因子VIIIa辅因子活性的突变蛋白,将K1813A、K1818A及双突变体在幼仓鼠肾细胞表达,并用纯化及整体凝血试验在血友病A小鼠模型中评估。K1813A对凝血因子IXa的Kd值低于野生型,kcat显著增大,凝血酶激活增强约1.3倍,活化后自发衰减减慢约2.5倍,热稳定性衰减减慢约2.5倍;在血友病A患者血样中0.5 nM K1813A的凝血潜能与1 nM野生型相当,小鼠尾剪试验中止血潜能较野生型高2至4倍。

要点

  • K1813A对凝血因子IXa的Kd值低于野生型(3.9±0.7 vs 6.3±0.3 nM)。
  • K1813A的kcat显著大于野生型,凝血酶激活较野生型增强约1.3倍。
  • 血友病A患者血样中0.5 nM K1813A凝血潜能与1 nM野生型相当。

核心结论

  • K1813A通过提高对凝血因子IXa的结合亲和力并增强凝血因子VIII/VIIIa分子稳定性,增强整体凝血潜能。

研究设计与样本

  • 将K1813A、K1818A及K1813A/K1818A突变体在幼仓鼠肾细胞中表达,采用纯化及整体凝血试验在血友病A小鼠模型中评估。

主要发现

  • 表面等离子共振显示K1813A对凝血因子IXa的Kd值为3.9±0.7 nM,低于野生型的6.3±0.3 nM。
  • K1813A对凝血因子IXa的Km值与野生型相当,kcat显著大于野生型。
  • 凝血酶催化的K1813A激活较野生型增强约1.3倍,活化K1813A的自发衰减较野生型减慢约2.5倍。
  • 热稳定性试验显示K1813A的衰减速率较野生型减慢约2.5倍。
  • 血友病A患者血样的凝血酶生成试验和旋转血栓弹力测定显示,加入0.5 nM K1813A的凝血潜能与1 nM野生型相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Factor VIII (FVIII) functions as a cofactor of FIXa for FX activation in the intrinsic tenase complex. The 1811-1818 region in the FVIII A3 domain was observed to contribute to FIXa binding, and the K1813A/K1818A mutant increased the binding affinity for FIXa. The current study aims to identify mutated FVIII protein(s) that increase FVIIIa cofactor activity in the 1811-1818 region. FVIII mutants with K1813A, K1818A, and K1813A/K1818A were expressed in baby hamster kidney cells and were followed by assessments using purified and global coagulation assays for mouse models with hemophilia A (HA). A surface plasmon resonance-based assay revealed that the Kd value of FVIII-K1813A for FIXa interaction was lower than that of the wild-type (WT) (3.9±0.7/6.3±0.3 nM). However, the Km value of FVIII-K1813A for FIXa on tenase activity was comparable with that of the WT, whereas the kcat of this mutant was significantly greater than that of the WT. Thrombin-catalyzed FVIII-K1813A activation was ∼1.3-fold more enhanced than that of the WT, and the spontaneous decay of activated FVIII-K1813A was ∼2.5-fold slower than that of WT. The heat stability assay revealed that the decay rate of FVIII-K1813A was ∼2.5-fold slower than that of WT. Thrombin generation assay and rotational thromboelastometry using blood samples from patients with HA demonstrated that the addition of FVIII-K1813A (0.5 nM) exhibited a coagulation potential compatible with that of WT (1 nM). In the tail clip assay of HA mice, FVIII-K1813A showed a two- to fourfold higher hemostatic potential than that of the WT. FVIII-K1813A, with higher a FIXa binding affinity, enhances the global coagulation potential because of the stability of FVIII/FVIIIa molecules.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nakajima Y, Takeyama M, Oda A, et al. Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential. Blood Adv. 2023. PMID: 36322904. doi:10.1182/bloodadvances.2022008187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。